GlassScriptPhysician profile
Donald Preate
NPI 1962473959
$8,498.86
in general payments reported to CMS, 2019-2025
34 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $1,697 · 2021: $1,509 · 2022: $1,059 · 2023: $1,093 · 2024: $898 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,054.53 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,329.82 | 2019-2025 | |
| Astellas Pharma US INC | $1,431.30 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $927.38 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $576.99 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $503.11 | 2019-2025 | |
| Teleflex LLC | $493.31 | 2021-2025 | Urolift, Barrigel |
| Urovant Sciences INC | $332.58 | 2021-2022 | |
| Coloplast Corp | $287.73 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $266.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $260.73 | 2019-2025 | Lynparza, Keytruda, Lenvima |
| Urogen Pharma, INC. | $121.01 | 2022-2025 | Jelmyto |
| Myovant Sciences INC. | $110.64 | 2021-2022 | |
| Boston Scientific Corporation | $85.84 | 2019-2025 | Spaceoar Vue System - 10ml, Axonics |
| Convatec INC. | $76.40 | 2025 | |
| Neotract INC. | $75.08 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photocure INC | $64.22 | 2024-2025 | Cysview |
| Antares Pharma, INC. | $62.54 | 2019-2021 | |
| Amgen INC. | $54.38 | 2020-2021 | |
| Pfizer INC. | $51.44 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $50.87 | 2023 | Prolaris |
| Takeda Pharmaceuticals U.S.A., INC. | $47.37 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $47.23 | 2023-2025 | Bard Urinary Drainage Bag |
| 180 Medical, INC. | $41.48 | 2024 | Gentlecath |
| Axonics, INC. | $41.32 | 2024 | Axonics, Bulkamid |
| Kerecis Limited | $18.18 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Tolmar, INC. | $18.08 | 2023 | |
| Dendreon Pharmaceuticals LLC | $17.94 | 2019 | |
| Endo Pharmaceuticals INC. | $17.51 | 2020 | |
| Olympus America INC. | $16.60 | 2025 | Bovie |
| Foundation Medicine, INC. | $16.04 | 2020 | |
| Medtronic, INC. | $15.46 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.34 | 2019 | |
| Karl Storz Endoscopy-America | $13.81 | 2025 | |
| Intuitive Surgical, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Preate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.